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Rigorous implementation research is important for testing strategies to improve the delivery of effective
osteoarthritis (OA) interventions. The objective of this manuscript is to describe principles of imple-
mentation research, including conceptual frameworks, study designs and methodology, with speciﬁc
recommendations for randomized clinical trials of OA treatment and management.
This manuscript includes a comprehensive review of prior research and recommendations for
implementation trials. The review of literature included identiﬁcation of seminal articles on imple-
mentation research methods, as well as examples of previous exemplar studies using these methods. In
addition to a comprehensive summary of this literature, this manuscript provides key recommendations
for OA implementation trials.
This review concluded that to date there have been relatively few implementation trials of OA in-
terventions, but this is an emerging area of research. Future OA clinical trials should routinely consider
incorporation of implementation aims to enhance translation of ﬁndings.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Practice gaps in osteoarthritis management
There are a number of evidence-based treatments for osteoar-
thritis (OA), including behavioral, rehabilitation, pharmacological,
and surgical strategies1e3. However, many studies show there are
gaps in the utilization or uptake of some treatment approaches in
real-world clinical practice4e12. For example, although exercise is a
core componentofmanagingOA, in a recent survey ofU.S. physicians,
less than one third said they would provide exercise advice for: K.D. Allen, 3300 Thurston
l: 1-919-966-0558.
Allen), s.bierma-zeinstra@
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eoarthritis Research Society Internpatients with knee OA13. Similarly, studies have shown that recom-
mendations for weight management for patients with OA are infre-
quent in clinical practice4,9,12. There is also evidence that
physiotherapy is underutilized5. For instance, among patients with
knee OA in two general practice regions in the UK, only 13% had ever
received physiotherapy14. With respect to pharmacotherapy, studies
have found inadequate attention to safety-related issues, particularly
with respect to use of nonsteroidal anti-inﬂammatorydrugs (NSAIDs)
among older adults15. With regard to surgical interventions, studies
document inappropriate use of arthroscopy16e18 and inequities in
joint replacement surgery19e23.Overall, studieshaveshownlow “pass
rates” formeeting quality indicators for OA-related clinical care9,15. In
one study of quality of care for community-dwelling adults with OA,
quality indicator pass rates ranged from 44 to 73% for recommended
non-pharmacological approaches and 27e59% for pharmacologicalational.
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OA across quality of care domains including effectiveness, safety, ac-
cess, and support for self-management10.
There are many factors that may contribute to these gaps in
translation of evidence-based OA care, including:
 Provider unfamiliarity with OA treatment recommendations.
For instance, one study showed that 2/3 of U.S. primary care
physicians were unfamiliar with OA treatment guidelines from
the Osteoarthritis Research Society International (OARSI)11.
 Lack of practical guidance within OA treatment guidelines, such
as indicators for when speciﬁc treatments may be appropriate
for subgroups of patients24.
 Lack of decision support tools and information technology
infrastructure to foster guideline-concordant OA care.
 Lack of incentives or quality measures for OAwithin health care
systems.
 Perception that OA is often seen as a degenerative condition for
which current interventions offer little help, therefore relegat-
ing OA to a low priority in terms of clinical treatment.
 Provider time constraints, which may particularly impact
counseling for behavioral strategies such as weight manage-
ment and exercise.
 Health care access issues, such as lack of insurance coverage (or
high co-payments) for services such as physiotherapy.
 Limitations in many prior studies with respect to external val-
idity and practical application in clinical settings, including:
+ Exclusion of many patients with medical and psychological
comorbidities common in patients with OA.
+ Lack of trials that directly compare different interventions,
particularly those that compare new interventions to estab-
lished ones.
+ Few studies conducted in primary care settings, where much
of OA care occurs.
+ Lack of studies examining organizational barriers and facili-
tators to implementing interventions.
Implementation research, deﬁned as research “focused on the
adoption or uptake of clinical interventions by providers and/or
systems of care25,” can test strategies to integrate evidence-based
OA interventions and improve practice patterns within clinical
settings. This manuscript provides an overview of conceptual
frameworks, study designs and methodology of implementation
research, with speciﬁc recommendations for randomized clinical
trials (RCTs) that test the implementation of evidence-based OA
care. Other implementation study types and intervention taxon-
omies have been described elsewhere26.
Methods
This review began with a search of Pubmed using terms of
“osteoarthritis” and “implementation.” We also conducted general
searches for manuscripts covering general RCT implementation
methods, covering each of the sub-topics below; from this litera-
ture we identiﬁed key study frameworks, designs and methods, as
well as other manuscripts of high relevance. Authors communi-
cated via a series of teleconferences and email correspondence to
identify additional topics and manuscripts for inclusion and to
develop and reach concurrence on a set of recommended principles
for OA implementation trials. Authors of this review included a
health services researcher and exercise physiologist, an academic
physiotherapist, an epidemiologist and physical therapist, a rheu-
matologist, and a clinical researcher in general practice and or-
thopedics; all had expertise in OA, including studies of care delivery
(including RCTs).Conceptual frameworks to guide implementation trials
For all types of RCTs, conceptual frameworks can help to guide
both development and evaluation of intervention strategies. The
following conceptual frameworks are examples that represent
different paradigms and have been applied to different in-
terventions and implementation studies:
RE-AIM framework
The RE-AIM framework, which stands for Reach, Effectiveness,
Adoption, Implementation, and Maintenance, can be used to assess
overall effectiveness of an intervention by emphasizing the repre-
sentativeness of participants and of settings27,28. RE-AIM provides a
systematic context for the assessmentof the impactof health behavior
interventions implemented at individual and organizational lev-
els29e31. The dimensions of “Reach” and “Effectiveness” focus on the
individual level, the “Adoption” and “Implementation” factors
examine the organizational level, and the “Maintenance” factor
comprises both levels. “Reach” assesses the proportion of the people
who receive or are affected by an intervention, as well as the charac-
teristics of the participants to determine representativeness. “Effec-
tiveness” examines positive andnegative outcomes of an intervention
to ensure that the beneﬁts outweigh the harms when applied to a
large population “Adoption” indicates the proportion and types of
settings that initiate an intervention, as well as barriers to adoption.
“Implementation” refers to how well the intervention is applied to a
population as originally planned and is thought to interact with efﬁ-
cacy todetermineoverall effectiveness. Lastly, “Maintenance” refers to
the long-term use or application of an intervention at the individual
and organizational levels. In the context of implementation trials, the
RE-AIM framework can be used both in the development and evalu-
ation stages. In the trial development phase, the ﬁve RE-AIM domains
can be used to plan an intervention with high likelihood for public
health impact. In the evaluation stage, assessment of all ﬁve RE-AIM
dimensions can provide comprehensive understanding of long-term
implementation potential and areas of weakness. The Practical,
Robust Implementation and Sustainability Model (PRISM) is a
comprehensive tool that can help researchers and policy makers
evaluate how interventions interact with recipients to inﬂuence ele-
ments in the RE-AIM framework, as well as other models32.
Knowledge-to-Action (KTA) framework
The KTA framework was developed by Graham and colleagues
to facilitate the use of research knowledge by stakeholders
including clinicians, policymakers, patients and the general pub-
lic33e37. The KTA process has two main components (Fig. 1): (1)
knowledge creation (inner cycle) and (2) action (outer cycle). Both
components have multiple phases, and the KTA process is typically
complex and iterative; knowledge and action phases can occur
sequentially or simultaneously and interact with each other. A key
characteristic of the knowledge creation “funnel” (Fig. 1) is that
knowledge becomes more distilled, reﬁned, and useful to stake-
holders during the process; this is a result of incorporating stake-
holder needs in each phase of the knowledge creation process. The
action cycle focuses on “deliberately engineering change in health
care systems and groups36.” Notably, stakeholder involvement is
also critical for action cycle phases (e.g., adaption and tailoring of
knowledge and interventions to the local context; Fig. 1). The action
cycle also includes monitoring of knowledge use to determine the
effectiveness of strategies and modify them accordingly, as well as
planning for sustained knowledge use.
The KTA process has been applied to a number of different
health conditions and settings35,38e42. For example, Tugwell and
Fig. 1. The KTA Process. From Graham, I. D. et al. (2006) Journal of Continuing Education in the Health Professions, Vol. 26, No. 1, 13e24.
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process to the management of musculoskeletal conditions, begin-
ning with knowledge from systematic reviews and working with
consumers through each knowledge and action phase to develop
tailored educational products38. A current RCT is using the KTA
framework to examine the effect of implementing an online pro-
gram for patients with rheumatoid arthritis43. The KTA framework
can be applied in the context of different RCT designs for imple-
mentation studies (described below), with components of the
knowledge creation and action cycles helping to determine the
most appropriate methods to answer key questions for consumers.
Theoretical Domains Framework
The Theoretical Domains Framework focuses on psychosocial
and organizational theory related to behaviors and behavior change
in clinical practice44. The designers of this framework concentrated
on the clinical behavior of the individual health professional
because health professionalepatient encounters are frequent,
essential components of health care that are important to the
quality of care and the success of the health of the patient44,45. This
framework includes 12 domains for health professional behavior
and behavior change: knowledge; skills; social/professional role
and identity; beliefs about capabilities; beliefs about consequences;
motivation and goals; memory, attention, and decision processes;
environmental context and resources; social inﬂuences; emotion;
behavioral regulation; and nature of the behaviors45. French et al.45
describe a four-step method for developing an implementation
intervention: (1) identifying target behaviors (the behavior change
needed to reduce the evidence-practice gap), (2) using the Theo-
retical Domains Framework to identify barriers and enablers to
change, (3) identifying techniques to change behavior in a feasible
and acceptable manner, and (4) conducting an implementation
intervention. The Theoretical Domains Framework is particularlyrelevant for implementation trials of interventions that focus pri-
marily on provider behaviors and patterns related to OA care.
Normalization Process Theory
The Normalization Process Theory provides a framework based
on sociological theory to bridge research, policy, and practice. This
framework was originally intended to help researchers and clini-
cians determine and understand factors that encourage or hinder
implementation of an intervention46. It has expanded to address
the participant's understanding, engagement, and support of the
intervention, along with the individual's evaluation of the inter-
vention, in an effort to understand social actions (what people
do)46,47. The Normalization Process Theory consists of four con-
structs: Coherence, Cognitive Participation, Collective Action, and
Reﬂexive Monitoring46. Coherence is the process of sense-making
that individuals and organizations experience when adding or
restricting a new practice or set of practices. Cognitive Participation
is the manner in which individuals and organizations encourage
participants to engage in a new practice. Collective Action is the
effort of individuals, teams and organizations together to imple-
ment a new practice. The last construct, ReﬂexiveMonitoring, is the
assessment of the positive and negative outcomes of the new
practice after its initiation and during its ongoing use. Normaliza-
tion Process Theory can be used in the evaluation stage of imple-
mentation trials, particularly for complex approaches that consist
of both treatment and organizational interventions, to help with
understanding factors that affect implementation processes.
Study designs for implementation trials
There are a number of study types and designs that can be
applied to implementation trials. Here we describe some of the
most common designs, including their general principles, some
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able, examples of OA trials. Fig. 2 shows a summary of these
designs.
Hybrid effectiveness-implementation trials
Curran et al. have introduced a typology of trial designs that
blends components of clinical effectiveness and implementation
studies25. The aim of this blended approach is to speed the uptake
of research ﬁndings into real-world clinical practice. Glasgow and
others have suggested that the typical time lag between discovery
and clinical uptake is partly due to the predominant research
pathway that begins with efﬁcacy studies, then effectiveness trials,
and ﬁnally implementation research28,48. Alternatively, these
stages of research can be blended in ways that result in more rapid
translation while preserving rigorous methodology25,28. Here we
focus on approaches for blending effectiveness and implementa-
tion research, as described in detail by Curran et al.25, which in-
cludes three broad types of designs. Hybrid Type 1 designs test a
clinical intervention (e.g., effectiveness) while also gathering in-
formation on its delivery (e.g., implementation) and/or its potential
for implementation in a real-world situation. Although the focus of
Hybrid Type 1 studies is still on the effectiveness of a clinical
intervention, they can simultaneously answer many questions
important for transitioning to implementation, such as organiza-
tion level barriers and facilitators. For example, two studies are
examining patient and provider interventions for managing OA inFig. 2. Summary of implemprimary care in different health care settings; primary hypotheses
are related to the effectiveness of the interventions, but
implementation-related analyses will evaluate facility/provider-
level variation and clinician feedback on the feasibility and poten-
tial for integration into routine OA care49. Hybrid Type 2 designs
involve simultaneous testing of a clinical intervention and an
implementation strategy. By directly blending effectiveness and
implementation aims, these study designs can lead to more rapid
provision of results that inform intervention delivery processes.
The Management of Osteoarthritis in Consultations Study (http://
www.controlled-trials.com/ISRCTN06984617) is an example of a
Hybrid Type 2 design; this cluster RCT is testing the feasibility,
acceptability and impact of implementing a new approach to sup-
porting self-management for OA in primary care in the UK. Study
aims include both evaluation of intervention effectiveness and
collection of process data and qualitative interview data regarding
barriers, facilitators, and other aspects of intervention delivery.
Hybrid Type 3 designs test an implementation intervention while
observing/gathering information on the clinical intervention and
related outcomes. Here the focus is primarily on implementation of
an intervention with established effectiveness, yet it may still be
important to evaluate the effects of the intervention when deliv-
ered in routine clinical practice, in speciﬁc settings or differing
conditions. Selection of an appropriate hybrid effectiveness-
implementation design depends on many factors, particularly the
current level of evidence for an intervention. Hybrid trials can
incorporate the speciﬁc study designs described below.entation trial designs.
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A distinction in trial design can be made between explanatory
(or efﬁcacy) and pragmatic (or effectiveness) trials50. Explanatory
trials test causal research hypotheses to determine whether an
intervention works in highly controlled (or ideal) conditions, usu-
ally with highly selected participants51. The comparison interven-
tion in an explanatory trial is often either a ‘no intervention’ control
or a placebo control. The results of explanatory trials may therefore
be of questionable generalizability to routine practice. Pragmatic
trials compare the effectiveness of interventions in everyday
practice with relatively unselected participants and under ﬂexible
conditions50,51. Therefore they help choose between options for
care under the usual conditions in which those options might be
offered. The key feature of pragmatic trials is high external validity
or generalizability, addressing the question ‘does this intervention
actually work in real life’ despite the complexity of real world
clinical services. For this reason pragmatic trials are extremely
helpful in informing decisions about routine practice51. Evidence
from pragmatic trials is most useful to policy makers in deciding on
whether to implement and allocate resources to new interventions
and services for patients with OA. Originally adopted by Schwartz
and Lellouch in 196752, the terms explanatory and pragmatic are
helpful to distinguish different types of trials, and although the
terms suggest a clean dichotomy (a trial is either explanatory or
pragmatic), in reality, there is a continuous spectrum50 with many
variations in elements including the breadth of eligibility criteria,
the ﬂexibility in intervention delivery, expertise of those delivering
treatment, degree of standardization of intervention protocol, effort
to ensure intervention compliance, and speciﬁc approaches to data
analyses. In addition, although pragmatic trials are often labeled
effectiveness trials, they typically incorporate many elements of
implementation research, including evaluation of feasibility and
barriers in real-world practice (e.g., Hybrid Type 1 or 2 categori-
zation as described above). The pragmatic-exploratory continuum
indicator summary (PRECIS) tool can help researchers assess the
degree to which trial design decisions alignwith its objectives (e.g.,
pragmatic/decision-making vs explanatory)50.
Pragmatic trials are being increasingly adopted to test the clinical
and cost-effectiveness of implementation interventions in the ﬁeld
of OA, since even well-studied interventions, with high-quality evi-
dence from robustly designed and performed explanatory trials, will
probably be less effective when tested in broader populations and
clinical services. Many pragmatic trials of interventions for OA are
complex, involvinganumberof separatebut interactingcomponents
that are likely to be important to the success of the intervention,
although the ‘active ingredients’ are often difﬁcult to specify. The
Medical Research Council Framework for the development and eval-
uation of complex interventions provides helpful guidance for these
types of studies53,54. In implementing a novel, complex intervention
(e.g., a new educational service comprising nurse-led clinics that
focus onexercises anddietaryadvice for peoplewithOAof the knee),
a rigorous process of development is needed to inform both the trial
design and intervention.What seems to be a sensible plan can easily
lead to a superﬁcial, ineffective intervention that is not adopted or
sustained in clinical settings; this emphasizes the importance of a
strong knowledge creation phase that closely involves key stake-
holders, as emphasized by the KTA framework. Ensuring compo-
nentsworkwell together is vital as it is easy for components to either
dilute the effect of each other or work against each other. Pragmatic
trials work best when they have large samples (to increase power to
detect small differences between the interventions being compared)
and simple designs (such as the simple, two-arm parallel design) as
thismakes the trial easier to plan, conduct and analyze. Evaluation of
complex interventions is also challenging53,54, and a key question istowhat extent trial investigators attempt to evaluate howa complex
interventionworks, i.e., to ‘tease out’ the effective ingredients in the
‘black box’. Pragmatic trials investigate the overall performance of
the intervention (with all the components working together) and
cannot identify the speciﬁc components that directly explain the
effectsobserved,unless trial teamsmakespeciﬁc additional efforts to
do this. For example, nurse-led clinics focused on exercise and diet
for OA might potentially work by some or all of the following:
improved conﬁdence and competence of the nursing staff in sup-
porting patients with OA to make behavioral changes, increased
access for patients to health professional support, decreased fear of
physical activity in patients, improved self-efﬁcacy and control over
symptoms, increased social interaction and participation, health
professionals' time, empathy, attention, and so on. Pragmatic trial
teams need to decide whether to measure these factors in order to
model an explanatory element, bearing in mind that the greater the
measurement burden themore likely selection andattrition biaswill
operate.
There are some key methodological challenges to consider with
pragmatic trials. First, bias or the systematic distortion of the esti-
mates due to poor design, conduct or analysis of a trial55, is partic-
ularly an issue for complex interventions where ‘real world’
estimates are paramount. Maximizing generalizability and access to
the key target group is important, requiring careful attention to how
the trial is communicated to potentially eligible patients and using
recruitment methods that avoid the recruitment of highly selected
participants, such as those that rely only on busy clinicians. Some
potential recruitment methods include using consultation-code
activated electronic tags or mailed invitation or population
screening surveys of registeredpatients. Second, there are challenges
concerningblindingofparticipantsandresearchpersonnel. Blinding,
or the masking of patients, practitioners, outcome assessors and
statisticians about the treatment to which an individual patient has
been allocated, is the traditional approach to try to prevent perfor-
mance and ascertainment bias in trials55,56. However, complex
implementation interventions, by their nature, may mean that the
usual types of blinding (patient and practitioner) are typically not
possible. In fully pragmatic trials, in which the speciﬁc ‘active’
ingredientof the intervention isnotof interest, placebo interventions
are rarely included, yet some blinding is often still possible50 and
feasible57 particularly of outcome assessment and during analysis.
An example of a pragmatic RCT is that of Gooch et al.58, who
tested the effectiveness of a new, evidence-based, clinical pathway,
compared to the usual care pathway, for patients undergoing pri-
mary hip and knee joint replacement. The new clinical pathway
was a clear example of a complex intervention, as it featured central
intake clinics, dedicated inpatient resources, care guidelines and
efﬁciency benchmarks. They used a simple design (two-arm par-
allel RCT), a large sample size (1570 patients) and had a clear pri-
mary outcome (WOMAC overall score 12 months following
surgery). Results showed that the evidence-informed clinical
pathway led to small but signiﬁcantly superior outcomes.
In summary, pragmatic randomized trials are an increasingly
popular design to test implementation interventions. In designing
pragmatic trials of complex interventions aimed at improving the
evidence-based treatment of OA, there are few ‘right’ answers. The
key is tobeclearat theoutsetof the trial, and toconductandreport the
trial robustly59 to facilitate appropriate interpretation. Clear thinking
about the key question and careful decision-making will maximize
the chance of the results inﬂuencing clinical practice for the better.
Cluster randomized trials
Cluster randomized trials are not unusual in pragmatic inter-
vention research for OA60e72. A cluster-randomized trial is one in
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general practices, physiotherapy practices, hospitals, workplaces, or
families are randomized. Although this trial design can be used
across phases of research, it has particular utility for effectiveness
and implementation studies.
Reasons for adopting cluster-randomized trials vary. A scientif-
ically obvious reason is that there might be a cluster action of the
intervention; an example of this is the treatment of transmittable
infections in which the treatment itself also reduces the trans-
mission of the disease73. This is not applicable in OA research, but
when interventions are given to a cluster (general practice, phys-
iotherapy practice, etc.) it might enhance participant motivation
and adherence by discussions between participants74. Another
obvious reason is that some interventions are targeted at the cluster
level and are aimed at the professional or (multidisciplinary) teams;
their care of patients can only be evaluated at cluster level75. A
frequently communicated reason for adapting cluster-randomized
designs is the avoidance of treatment group contamination. For
example, when an intervention transmits knowledge contamina-
tion towards the control or alternative intervention group, this
should be avoided by separation of the groups in space or time75.
Overall, cluster-randomized trials are particularly appropriate for
evaluation of interventions that aim to change behavior of either
the professional or the patients or aim to change the organization of
providing treatments or referrals76.
There are several issues that require speciﬁc attention in cluster-
randomized trials. The ﬁrst of them concerns informed consent
procedures. This procedure in cluster-randomized trials might differ
from the usual procedures when individuals are randomized.
Recently, The Ottawa Statement on the ethical design and conduct
of cluster randomized controlled trials gave guidance for the
informed consent procedure in a range of particular situations77. In
trials where the intervention is aimed at the professional and
contains, for example, a novel management program for OA, one
might only seek consent to data collection but not to the inter-
vention or randomization from the patient78. In such cases the
clinicians or practice leads provide consent to randomization on
behalf of their patients. The practice in which the patient partici-
pates is already randomized and all patients undergo the man-
agement according to randomization. However, information can be
provided even if the patient does not have a feasible alternative
intervention and cannot withdraw75. The value of courteously
providing information to patients should not be underestimated,
although it is possible that this results in either an increase in
goodwill, or an increase in patient concern. Failure to provide this
information risks psychological harm, as subsequent discovery of
inclusion in an experiment might result in a sense of violation79,80.
There are no clear rules for the degree to which such information
should be given; this depends on the type of intervention studied
and the potential to withdraw from the intervention or data
collection, and should therefore be covenantedwith patient boards,
the professionals and ethical committees involved. In some sce-
narios patient consent may be required, but it is not feasible to
obtain consent prior to the clusters being randomized; in these
situations the Ottawa statement recommends obtaining consent of
patients as soon as is feasible after cluster randomization.
Another issue in cluster randomized trials is recruitment bias;
there can be lack of blinding to allocation status of those identifying
or recruiting individuals into a cluster randomized trial because
individuals may be recruited to the trial after the clusters have been
randomized76,81. The knowledge of whether each cluster is an
‘intervention’ or ‘control’ cluster could affect the types of partici-
pants recruited. Farrin et al. showed differential participant
recruitment in a pilot trial of low back pain randomized by primary
care practice; a greater number of less severe participants wererecruited to the ‘active management’ practices82. The design of the
main trial was therefore changed from a randomization on cluster
level (practices) towards a randomization on patient level stratiﬁed
by practice83. In some situations, however, it is possible to blind
participants and those recruiting participants to the cluster
assignment at the time of enrollment49.
The lack of independence among individuals within the same
cluster (intracluster correlation) has implications for the sample size
calculation. Standard sample size approaches lead to an under-
powered study. The inﬂation in sample size depends on average
cluster size and the degree of correlation within clusters, r, also
known as the intracluster (or intraclass) correlation coefﬁcient
(ICC). If m is the cluster size (assumed to be the same for all clus-
ters), then the inﬂation factor, or “design effect,” associated with
cluster randomization is 1þ(m1)r81. Although typically r is small
(often <0.05) and is often not known when a trial is planned (and
can only be estimated with error after a trial is completed), its
impact on the inﬂation factor can be considerable when clusters are
large. In general, the power is increased more easily by increasing
the number of clusters rather than the cluster size84.
Cluster-randomized controlled trials also present special re-
quirements for analysis. The data could be analyzed as if each
cluster was a single individual, but this approach ignores the in-
formation collected on all participants within a cluster and hence
may not use the full richness of the dataset84. When analyses are on
the patient or participant level, many cluster-randomized trials are
analyzed by incorrect statistical methods, not taking the clustering
into account. For example, Eldridge et al. reviewed 152 cluster-
randomized trials in primary care of which 41% did not account
for clustering in their analyses85. Such analyses create a ‘unit of
analysis error’ and produce over-precise results (the standard error
of the estimated intervention effect is too small) and P values that
are too small. If simple statistical tests are used to compare effects
on the patient level, adjustments have to bemade to account for the
clustering effect. For example, test statistics based on chi-squared
or F-tests should be divided by the design effect (as described
earlier), while test statistics based on the t-test or the z-test should
be divided by the square root of the design effect86. However,
several modeling techniques can incorporate patient level data
such as mixed linear models, hierarchical linear modeling and
generalized estimating equations. These modeling techniques
allow the inherent correlation within clusters to be modeled
explicitly, and thus a ‘correct’ model can be obtained87.
Reporting on cluster-randomized trial requires additional infor-
mation. In 2012 Campbell et al.84 reported the extension to the
CONSORT 2010 statement in which recommendations for the
reporting of cluster randomized trials are presented. The main
problem associated with their design, conduct, analysis, and
interpretation, compared with individually randomized trials, is
that two different units of measurementdthe cluster and the
patientdare used. Each needs to be reported carefully84.
A clear example of a cluster randomized controlled trial is the
ARTIST study reported by Ravaud et al., which compared a novel
management program with usual care for knee OA62. The care
management program involved standardized consultations, pro-
vided during three goal oriented visits (education on OA and
treatment management; information on physical exercises; infor-
mation on weight loss). In this study the rheumatologists were
randomized and not the individual patients. Each rheumatologist
had to include the ﬁrst two patients who complied with the in-
clusion criteria. Patients were informed that they were partici-
pating in a trial comparing different forms of consultations. They
were informed about the content of the consultations towhich they
were assigned but not the consultation programm the other arm
received. The primary outcomes were measured at patient level;
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cises at 4 months. Taking the clustering effect into account, the
decrease inweight as well as the physical activity score was greater
in the standardized consultation group than in the usual care group.
Stepped wedge designs
Stepped wedge randomized trials involve sequential roll-out of
a new intervention to the units of randomization (either individuals
or, more often, clusters such as primary care practices, hospital
clinics or geographical districts), such that each unit ‘steps’ from
offering the control intervention to the new intervention over time.
In this design, all randomized units eventually have the new
intervention, although the order in which they receive it is deter-
mined at random88. The stepped wedge design can be described as
a type of crossover design in which different clusters cross over at
different time points, but only in one direction; from offering the
control to offering the new intervention89. More than one cluster or
unit of randomization may start the new intervention at any given
time point, but the time at which the new intervention begins is
randomized. For example, a trial including 12 primary care prac-
tices might randomly allocate one practice each month for 12
months, such that each month one practice changes from offering
usual care for patients with OA (the control phase) to a new
evidence-based intervention (the intervention phase). In this
example, one primary care practice will have only 1 month of of-
fering usual care before it steps up to offer the new intervention,
and at the other end of the trial, one practicewill offer usual care for
a year before it steps up to deliver the new intervention. Alterna-
tively, the same trial may choose to randomly allocate two or three
practices per month to step up to the new intervention, shortening
the overall length of the trial. The stepped wedge design necessi-
tates baseline data collection at the time when none of the clusters
or units receive the new intervention, as well as data collection at
each point in all clusters or units when a new unit or group receives
the new intervention88,89. The overall effectiveness of the new
intervention is determined by comparing the data from the control
phase and the intervention phase from all the randomized units.
Stepped wedge designs are thought to be particularly useful for
evaluating the overall impact of an intervention (e.g., a new
implementation strategy for best practice for OA), where the new
intervention or strategy has either already been shown to be
effective in an individually randomized trial (the so-called phase IV
effectiveness trials)89 or where there is general consensus by the
relevant stakeholders that the new intervention provides more
good than harm (i.e., in cases where there is a lack of true collective
equipoise about the merits of the new intervention)88,89. The
design has also been justiﬁed in some cases where the intervention
under investigation is already a recommended or adopted policy
but lacks evidence of effectiveness90. It may also be the design of
choice if there are ﬁnancial, logistical or operational reasons that
make it impossible to provide the new intervention simultaneously
to many randomized units at the same time88 but rather where
phased implementation is preferable. In the example above, it
might be the case that the new intervention is supported by only
one implementation facilitation team that must travel to each
participating primary care practice in turn. In addition, a stepped
wedge design might be justiﬁed where there are doubts about
whether beneﬁcial effects seen by a new intervention in a tradi-
tional randomized trial are reproducible in the real world when
scaled up to larger populations and communities91.
There are many purported advantages of the stepped wedge
design. The design may increase the motivation of participants or
clusters to take part in the trial (as they will all eventually receive
the new intervention)92, it may help address the dilemma ofwithholding the new intervention when there is no collective
equipoise in the scientiﬁc or clinical community, and it can be
helpful to study the effect of context given that the intervention is
implemented in multiple settings with often different character-
istics (and the intervention may work in some but not all of these
settings). In addition, the phased implementation of the new
intervention in the stepped wedge design means that it is possible
to improve the intervention or its implementationwhere necessary
before the next unit is randomized93, the design can help to detect
trends in the effectiveness of the intervention over time by con-
ducting a step-by-step comparison, and can increase statistical
power as the design involves both within and between cluster
comparisons89.
A key disadvantage is that the timeline for the trial is usually
extended, so stepped wedge trials often are lengthier in total than
the equivalent simple, two or three arm parallel trial design. It is
also not well suited to testing some types of interventions, as it is
ideal if there are short time intervals between the application of the
intervention and the expected change in key outcomes90. Where it
is important to also measure longer-term outcomes (follow-up
participants beyond the time period inwhich stepping takes place),
this maymean the trial length extends beyond the timelines within
scope of many research funders. Multiple data collection points are
required, which can be burdensome for participants or clinicians
and ﬁnancially expensive and therefore, ideally, stepped wedge
trials make use of routinely collected data. Finally the data analysis
of this type of trial is more complicated than other designs89.
Particular analysis challenges are controlling for temporal trends in
outcome variables and accounting for repeated measures on the
same participants throughout the trial88.
There are also some key challenges with this design. Preventing
contamination between the clusters receiving the new intervention
and those still waiting to step up to the new intervention can be a
problem, as can ensuring some level of blinding. Since it is often
impossible to blind participants or those delivering the interven-
tion (as both will usually be aware of the step from control to the
new intervention), blinding assessors is important88. The clusters
are randomly allocated to the time at which theymove from control
to the new intervention, and thus all of the preparatory work must
be completed with each unit of randomization such that they are
indeed ‘ready’ to implement the new intervention at the timeslot in
which they are randomized to do so. This can be particularly
challenging where the new intervention involves signiﬁcant new
training for personnel, where new systems need to be adopted to
provide the new intervention in a timely fashion, or indeed where
there are multiple other competing priorities that may get in the
way of the cluster being able to change to the new intervention at
the randomized timeslot (e.g., primary care practices that are
subject to multiple competing priorities and unforeseen circum-
stances that must be made a higher priority). In a cluster stepped
wedge trial, an important decision is the number of clusters ran-
domized at each time step, given that optimal power is obtained
when each cluster is randomized to the new intervention at its own
randomization step89. Randomizing multiple clusters at each time
point reduces the overall number of measurement time points and
this signiﬁcantly reduces power. Like classic cluster randomized
trials, sample size calculations need to include the cluster design
effect (the intraclass correlation coefﬁcient)90. In addition, stepped
wedge designs may not be suitable for testing all interventions,
since those for which the full treatment effect is not expected to be
realized for some time (until more than one time interval after the
intervention is introduced) also signiﬁcantly reduces power. It is
desirable to ensure that each measurement time period is long
enough so that the effect of the new intervention is fully realized
before the next time period begins89.
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evaluating intervention effectiveness during routine implementa-
tion. Two systematic reviews have shown that stepped wedge trial
designs are increasingly used in the health research ﬁeld to eval-
uate the implementation of interventions in routine practice88,90,
with the number of steps ranging from 2 to 36 steps and the period
between steps ranging from 12 days to 1.5 years90. However, many
stepped wedge designs published so far do not fulﬁll the method-
ological requirements of a controlled trial88, and many do not
ensure blinded assessment of key outcomes. Whilst the stepped
wedge design has many advantages and their use has been advo-
cated88, the choice of a stepped wedge trial over a classic cluster
RCT is not without controversy94, and careful planning is needed to
address the known challenges. To date, as far as we know, there are
no completed, published stepped wedge randomized trials specif-
ically addressing the implementation of best practice in OA,
although there is a lack of consistency in reports clearly describing
trial design as a stepped wedge90.
An example of a trial currently in progress that is relevant to OA,
rather than speciﬁcally focused on OA, is the cluster randomized,
stepped wedge trial from Dreischulte et al.95. Their team is testing
the effectiveness of a multi-faceted information technology-based
intervention in reducing high-risk prescribing of nonsteroidal
anti-inﬂammatory and anti-platelet medications in primary care
(The DQIP study). The study involves 40 general practices (family
practices) in Scotland, which will be randomized to one of 10 start
dates (at four weekly intervals). Due to the nature of the complex
intervention (involving a web-based informatics tool that provides
weekly feedback at practice level, prompts the review of patients
and summarizes each patients risk factors, as well as educational
outreach visits to practices and payments for each patients
reviewed), it is not possible to blind practices, the core research
team or the data analyst. However, the outcome assessment is
objective and completely automated. Outcomes during the DQIP
intervention will be compared to care before its introduction. Their
rationales for selection of the stepped wedge design are both
logistical (they need to stagger the start of the new intervention at
the different practices as they need to deliver educational outreach
visits) and related to concerns about practices dropping out of the
trial (a conventional two arm design would mean no ﬁnancial in-
centives to practices in the usual care arm).
Adaptive trial designs and adaptive interventions
Adaptive trial designs allow for planned modiﬁcations of the
study, based on accumulating data96,97. There are many options for
adaptive trial designs96,98, but the overarching goals are to improve
trial efﬁciency, reduce sample size, and/or increase the likelihood of
ﬁnding an effect if one does exist99. Adaptive clinical trial designs
have been utilized for decades in pharmaceutical research and
other efﬁcacy and effectiveness trials98, with little application to
implementation research to date. However, these methods can
certainly be applied to implementation research to improve efﬁ-
ciency of these studies. Adaptive interventions involve a sequence of
individually tailored decision rules that specify whether, how, and
when the intensity, type or delivery method of an intervention is
altered for a given study participant100. For example, these in-
terventions often involve increasing the intervention intensity in
some way if participants fail to meet speciﬁed benchmarks for
improvement or response101. Although we know of no completed
adaptive interventions trials for OA treatment, some studies have
evaluated adaptive interventions for physical activity and weight
management (key behavioral strategies for OA) in other patient
groups102,103. Sequential Multiple Assignment Randomized Trials
(SMART) are one type of adaptive intervention, involving multiplestages at which participants are randomized to a set of treatment
options104e106. Adaptive interventions have most commonly been
applied to effectiveness trials101 but have recently been utilized in
implementation research107. In this context, adaptive interventions
can allow clinical settings or patients not responding to an initial
implementation strategy to receive an augmented or different type
of intervention107.
Process and formative evaluations in implementation trials
Implementation trials generally have as their goal improvements
in quality of care through delivery of interventions designed to drive
research evidence into real-world clinical practice. As such, the in-
terventions being evaluated are often complex, with multiple
interconnecting parts or components108, must be tailored to local
circumstances (available human and other resources)54, and require
substantial investment of resources to implement. As a result, a
phased, non-linear54,109 approach to evaluation,which incorporates
considerable pilot work, and both formative (outcome) and process
components to the evaluation, is recommended34,37,110e112.
Formative or outcome evaluations measure the degree to which
the research objectives have been achieved (did the intervention
work?). As the key question being addressed in an implementation
trial is whether or not the intervention is effective in everyday
practice113, formative evaluation of an implementation trial should
incorporate validated measures of effectiveness and cost effec-
tiveness that are relevant to patients, providers and other key
stakeholders, such as policy makers, commissioners or payers of
services, and administrators114. While a single primary outcome
and a small number of secondary outcomes might be most
straightforward, this approachmay notmake best use of the data or
provide an adequate assessment of the success of an intervention
across a range of domains54. As a result, a priori consideration of a
range of outcome measures, including measures of unintended
consequences, may be preferred. Regardless of which outcome
measures are selected, each should be evaluated to ensure its
feasibility, validity and responsiveness in the context of the pro-
posed intervention prior to trial implementation.
For complex interventions, however, it is also e if not equally e
important to ensure the intervention components are likely to
succeed in achieving the desired outcomes, and once launched, to
understand how the intervention works (e.g., what are the active
ingredients and how are they exerting their effects?). Thus process
evaluations are often used in pre-testing the components of the
intervention to enable their reﬁnement before the trial is
launched108. For example, the success of many complex in-
terventions depends on its acceptability to the participating clini-
cians, patients or other key stakeholders108,115. In the quality
improvement arena, both barriers to and facilitators of clinician
engagement in such initiatives have been elucidated116e118. Atten-
tion to ensuring identiﬁed barriers have been overcome and facil-
itators optimized is therefore key to address in implementation
trial pilot work119. Process evaluations can also be nested within an
implementation trial to assess the ﬁdelity and quality of imple-
mentation, clarify potential causal mechanisms, and identify
contextual factors associated with variation in outcomes120,121.
Within the context of a multi-site implementation trial, where the
same intervention may be implemented and received in different
ways, process evaluation is particularly necessary. For example,
process evaluation is useful in determining whether or not lack of
an intervention effect was due to implementation failure or
genuine ineffectiveness. Process evaluation can furthermore pro-
vide valuable insight into one or more of the following: why an
intervention fails or has unexpected consequences, how a suc-
cessful interventionworks and how it can be optimized, differential
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an intervention, reach of the intervention, and the way effects vary
in subgroups122.
Mixed qualitative and quantitative methods are often required
to perform a comprehensive process evaluation e to provide a
detailed understanding of variations within and interactions be-
tween the components of the intervention123. Strategies that may
be used to collect process level information include: semi-
structured interviews where open ended questions regarding
feelings, knowledge, opinions, experiences, perceptions are used
and data recorded; focus groups; semi-structured and structured
in-depth interviews using key informant or other community
members; Delphi method using expert opinion and reiteration;
observations from ﬁeldwork descriptions of activities; and case
studies124. Ideally, process evaluation is performed and analyzed
before the formative trial outcome data in order to avoid bias in
interpretation. While incorporating a qualitative component to the
process evaluationwill increase research costs, greater cost must be
balanced against the potential for greater explanatory power and
understanding of the generalizability ﬁndings and potential for
sustainability of the intervention125.
Limitations
Althoughwe aimed to provide a comprehensive review of topics
related to implementation research and its application to OA RCTs, a
formal systematic review was not conducted due to the broad
scope of the manuscript. There are other theoretical models
applicable to implementation research, as well as detailed re-
sources describing implementation research methods34,126.
Facilitators and barriers of implementation strategies
Theoretical frameworks such as RE-AIM and KTA provide guid-
ance on strategies to facilitate successful development and evalua-
tion of interventions that are of value to stakeholders and can be
adopted and sustained in clinical settings. However, there are
common barriers to implementation studies, including: identifying
and engaging all of the appropriate stakeholders and consumers,
differing priorities among stakeholders, logistical challenges to
weaving new interventions and processes into real-world clinical
settings, competing priorities within clinical settings, and identi-
fying resources and motivated leadership to sustain effective in-
terventions or practices. Implementation research is a relatively
young but rapidly emerging ﬁeld; much is still unknown about the
most effective strategies for implementation and knowledge
translation, particularly when targeting policymakers and broad
organizational culture127,128. However, there is some evidence that
multifactorial interventions are more effective than single in-
terventions129. In addition, conﬁrming principles of the KTA
framework, a systematic review showed that tailored interventions
to overcome identiﬁed barriers to changing clinical practice are
more effective than general dissemination of guidelines130.
Summary principles for OA implementation trials
The following are key principles for OA implementation trials,
generated by consensus of co-authors and based on general guid-
ance for implementation research, best practices for development
and evaluation of complex interventions, speciﬁc needs and con-
siderations related to OA and its treatment:
1. Implementation studies are essential for testing whether results
translate into real-world practice, and more of these types of
RCTs are needed to informwhich strategies support real changein practice for managing OA. Based on this need, it is recom-
mended that all RCTs evaluating the effectiveness of OA treat-
ments: (1) consider issues of generalizability in all aspects of the
study design131 and (2) whenever possible, incorporate imple-
mentation aims that will inform future uptake or delivery of
effective interventions25.
2. Development of OA implementation interventions should
involve a rigorous developmental phase, including consider-
ation of relevant theoretical frameworks and ensuring feasibility
and acceptability to stakeholders45,53,54.
3. OA implementation trials should utilize recruitment methods
and participant inclusion/exclusion criteria that maximize
generalizability. For example, patients should represent a range
of general health states and resources to enact behavioral
change, and healthcare professional participants should repre-
sent a broad range in terms of clinical experience and interest
level in the clinical condition of OA.
4. OA implementation trials should involve strong analytic plans
for evaluating both processes and outcomes54.
5. Costs and cost effectiveness of implementation strategies should
be considered as outcomes for OA implementation trials, and
these should follow best practices for RCTs132.
6. Complex interventions, often the focus of implementation trials,
may work best if tailored to local circumstances53,54. Therefore
OA implementation trials should consider interventions that
allow some ﬂexibility in the delivery approach.
7. Given the plethora of potential study designs from which to
choose, teams studying implementation of best practice in OA
need to clearly justify their choice, and attend to the challenges
associated with their design.Author contributions
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